Medicines & Treatments
Sermorelin & GHRP-6 & GHRP-2 Blend (9mg)
Blending the peptides Sermorelin, GHRP-2, and GHRP-6 may be practical for researchers aiming to investigate the potential of stimulating pituitary cells (somatotrophs) via multiple pathways. Specifically, these three peptides appear to interact with pituitary cells via different receptors. Sermorelin is a research peptide made of 29 amino acids that is a shortened version of the endogenous 44 amino acid structure of Growth Hormone-Releasing Hormone (GHRH). Similar to its endogenous counterpart, Sermorelin appears to interact with the cells via the GHRH-receptor, which is also considered the main receptor for stimulating growth hormone (hGH) release from the pituitary cells. GHRP-2 and GHRP-6 are fully synthetic peptides that are posited as growth hormone secretagogues (GHSs) as they appear to interact with another set of receptors on the somatotrophs. Specifically, those are the growth hormone secretagogue receptors type 1a (GHS-R1a), which also respond to the hormone ghrelin. Despite sharing no homology with ghrelin, GHRP-2 and GHRP-6 appear to reliably activate the GHS-R1a and also stimulate hGH release from the pituitary cells. Several experiments suggest that simultaneously activating the GHS-R1a and GHRH receptors may produce combined and synergistic actions. Chemical Makeup Other Known Titles Sermorelin: GRF 1-29 NH2 GHRP-2: pralmorelin GHRP-6: SKF-110679, growth hormone-releasing hexapeptide Molecular Weight: Sermorelin: 93 g/mol GHRP-2: 97 g/mol GHRP-6: 03 g/mol Molecular Formula: Sermorelin: C149H246N44O42S GHRP-2: C45H55N9O6 GHRP-6: C46H56N12O6 Research and Clinical Studies Sermorelin & GHRP-2 & GHRP-6 Receptor Interactions According to research by Clark et al., Sermorelin appears to interact with the GHRH receptors.(1) This is allowed by its structure as it is the shortest functional analog of endogenous GHRH with a C-terminal amidation that may help stabilize the molecule. According to studies by Culhane et al., it appears to activate the GHRH receptors through several steps, which may involve the activation of an intracellular messenger called cyclic AMP (cAMP) and the kinase PKA (protein kinase A), which together may switch on the cellular machinery that synthesizes and releases hGH.(2) There does not appear to be desensitization according to the available laboratory research. The resulting hGH synthesis may have direct and indirect actions. The indirect may be via its anabolic mediator IGF-1 (insulin-like growth factor-1), which is produced in other tissue cells when they are presented with hGH. GHRP-2 and GHRP-6 appear to interact with the GHS-R1a, also referred to as the ghrelin receptors. However, these two hexapeptides have no similarities with ghrelin in terms of structure, as highlighted by the work of Bowers et al in 2012.(3) Furthermore, laboratory research by Yin et al. suggests that they may exert a chain of intracellular cascades and events in somatotrophs by interacting with these receptors. Researchers posit that GHRP-2 and GHRP-6 may activate the receptors by interacting with the enzyme phospholipase C (PLC), which cuts a specific membrane molecule (PIP₂) into two smaller signaling molecules called IP₃ and DAG. The latter may help switch on another enzyme family called protein kinase C (PKC), which is posited to interact with protein synthesis related to hGH synthesis. On the other hand, IP₃ appears to interact with the internal calcium stores of pituitary cells, causing Ca²⁺ to be released into the cytoplasm, which may then release hGH molecules out of the pituitary cells. Sermorelin & GHRP-2 & GHRP-6 and hGH Synthesis Laboratory work in pituitary cell models suggests that exposing somatotrophs to Sermorelin may upregulate hGH synthesis, although the specific action size varies between studies. For example, in an experiment reported by Vittone et al., the mean 12-hour growth hormone concentrations were described as rising about 2-fold from about 1.1 ± 0.9 µg/L to roughly 2.2 ± 1.9 µg/L.(5) The cumulative hGH output for these 12 hours also appeared to increase 2-fold, from around 1,114 ± 931 to about 2,032 ± 1,728 µg·min/L. Additional work by Khorram et al. suggests that the increase may particularly occur during the first 2 hours of exposure, while longer windows may blend early peaks with later, lower-amplitude release.(6) They employed a slightly modified Sermorelin molecule. They described that the 2-hour integrated growth hormone signal appeared to shift from roughly 200–300 to about 1,100–1,600 µg·L⁻¹·min, which is close to a sixfold rise. GHRP-2 and GHRP-6 also appear to induce short-term peaks in hGH levels. For example, older research by Bowers et al. from 2004 suggests that under continuous 24-hour evaluation, GHRP-2 may also increase growth hormone production from approximately 20–30 µg·L⁻¹·24 h in placebo controls to about 120–180 µg·L⁻¹·24 h with GHRP-2, suggesting an estimated 4- to 6-fold increase. On the other hand, research by Micic et al. investigated peak growth hormone responses of pituitary cells after stimulation with GHRP-6 and reportedly observed a rise from basal 1–2 mU/L to around 60 mU/L.(8) Based on this data, the peptide may induce peaks that exceed 3-fold the typical physiological peaks that may reach about 20 mU/L. Indeed, the researchers also commented that “GH responses to GHRP-6 are much greater than to GHRH”. Sermorelin & GHRP-2 & GHRP-6 and Anabolic Signaling Based on the aforementioned publications by Khorram et al. and the research by Bowers et al., from 2004 suggest that the peptides may induce a significant stimulation of hGH synthesis in pituitary cells that may then prove to be sufficient to induce IGF-1 synthesis in nearby cell cultures.(6)(7) More specifically, Khorram et al. suggested that there has been about a 27–28% increase in IGF-1 synthesis following Sermorelin experimentation. With the GHRP-2 exposure for 24 hours, Bowers et al. suggested that the IGF-1 levels may have increased from 90–100 µg/L to approximately 150–160 µg/L, which is equal to roughly a 50–80% increase. Unfortunately, the GHRP-6 experiment by Micic et al. was too short to report any data on IGF-1 synthesis.(8) Sermorelin & GHRP-2 & GHRP-6 and Synergistic Actions Blending Sermorelin with GHRP-2 and GHRP-6 is often framed as a practical way to evaluate dual-receptor stimulation in somatotroph systems. When both receptor families are activated at the same time, several experimental datasets suggest that growth hormone output may rise beyond what is seen with either pathway alone, which is compatible with additive or synergistic coupling at the level of pituitary signaling. Unfortunately, most of the experiments have evaluated GHRP-2 or GHRP-6 with full-length GHRH rather than Sermorelin, but such results are valuable for future research. For example, the pituitary models described by Micic et al. reveal that GHRP-6 alone was associated with a peak growth hormone response around 60 mU/L, while the combination of GHRP-6 with full-length GHRH was reported to raise the peak to roughly 140 mU/L, or 7-fold higher than the highest physiological peaks.(8) Cordido et al. also suggested that GHRP-6 alone produced an average peak around 6 mU/L, while the GHRH analogue alone produced a smaller peak near 2.6 mU/L. When both secretagogues were applied together, the peak rose to about 16.3 mU/L. Their integrated 12-hour data followed the same direction. The reported 12-hour growth hormone exposure was around 260 mU·min/L with GHRP-6 alone and about 159 mU·min/L with the GHRH analogue alone, but increased to roughly 729 mU·min/L when the two were combined.(9) Comparable synergy signals have been reported for GHRP-2 when combined with endogenous, full-length GHRH in experimental pituitary systems. In the work by Veldhuis et al., each peptide produced a large outcome on its own. However, the combination still yielded an extra increment. (10) In their models, GHRH alone was estimated to raise growth hormone burst output by roughly 20-fold over baseline. At the same time, GHRP-2 alone was associated with an even larger rise, around 47-fold. When both stimuli were present, the calculated response increased to about 54-fold above saline, which corresponds to a modest additional gain over GHRP-2 alone. The aforementioned 2004 research on GHRP-2 by Bowers et al. also included GHRH co-evaluation and concluded that the “combined GHRP-2 and GHRH drive is more effective than either agonist alone.”” Currently, only the research by Sigalos et al. evaluated a combination of Sermorelin with both GHRP-2 and GHRP-6.(11) Their findings suggest an upward shift in IGF-1 from baseline values around 160 ng/mL to roughly 250–265 ng/mL, which corresponds to an apparent 1.6-fold increase. Because the design involved multiple peptides and did not isolate each contribution, the data do not map cleanly onto a single receptor-pair interaction. Still, the direction of change is compatible with the broader observation that GHRH-receptor input and GHS-R1a input may cooperate to increase downstream hGH output. Sermorelin & GHRP-2 & GHRP-6 blend is available for research and laboratory purposes only. Please review our Terms and Conditions before ordering. References: Clark RG, Robinson IC. Growth induced by pulsatile infusion of an amidated fragment of hGH-releasing factor in normal and GHRF-deficient rats. Nature. 1985 Mar 21-27;314(6008):281-3. doi: 10.1038/314281a0. PMID: 2858818. Culhane KJ, Liu Y, Cai Y, Yan EC. Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol. 2015 Nov 5;6:264. doi: 10.3389/fphar.2015.00264. PMID: 26594176; PMCID: PMC4633518. Bowers CY. History of the discovery of ghrelin. Methods Enzymol. 2012;514:3-32. PMID: 22975043. https://doi.org/10.1016/B978-0-12-381272-8.00001-5 Yin Y, Li Y, Zhang W. The growth hormone secretagogue receptor: its intracellular signaling and regulation. Int J Mol Sci. 2014 Mar 19;15(3):4837-55. doi: 10.3390/ijms15034837. PMID: 24651458; PMCID: PMC3975427. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997 Jan;46(1):89-96. doi: 10.1016/s0026-0495(97)90174-8. PMID: 9005976. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997 May;82(5):1472-9. doi: 10.1210/jcem.82.5.3943. PMID: 9141536. Bowers, C. Y., Granda, R., Mohan, S., Kuipers, J., Baylink, D., & Veldhuis, J. D. (2004). Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. The Journal of clinical endocrinology and metabolism, 89(5), 2290–2300. https://doi.org/10.1210/jc.2003-031799 Micic D, Popovic V, Kendereski A, Macut D, Casanueva FF, Dieguez C. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin Endocrinol (Oxf). 1995 Feb;42(2):191-4. doi: 10.1111/j.1365-2265.1995.tb01861.x. PMID: 7734029. Cordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 1993 Apr;76(4):819-23. doi: 10.1210/jcem.76.4.8473389. PMID: 8473389. Veldhuis JD, Keenan DM. Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. Eur J Endocrinol. 2008 Nov;159(5):547-54. doi: 10.1530/EJE-08-0414. Epub 2008 Aug 14. Erratum in: Eur J Endocrinol. 2008 Dec;159(6):841. PMID: 18703567; PMCID: PMC2680123. Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017 Nov;11(6):1752-1757. doi: 10.1177/1557988317718662. Epub 2017 Aug 22. PMID: 28830317; PMCID: PMC5675260. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Decapeptide-12 (200mg)
Decapeptide-12 is a synthetic peptide that is composed of 10 amino acids. Its developers and subsequent researchers have suggested that Decapeptide-12 may potentially inhibit melanin production in the skin by suppressing the activity of tyrosinase, an enzyme involved in the synthesis of melanin. Decapeptide-12 does not appear to mimic any naturally occurring peptide. Rather, it was designed and synthesized to exhibit specific properties. Decapeptide-12 is primarily researched in reducing melanin production and hyperpigmentation. It has also been studied for its potential impact on cell growth, differentiation, and mitigating cell aging. However, more research is needed to fully understand the potential properties and results of Decapeptide-12 experiments in these contexts. Chemical Makeup Molecular Formula: C65H90N18O17 Molecular Weight: 1311.46 g/mol Overview and Mechanisms of Action As mentioned, Decapeptide-12 is posited to work primarily by inhibiting melanin synthesis, aka melanogenesis. Melanin synthesis is suggested to be a complex biochemical pathway that may occur within specialized cells in the skin called melanocytes. Tyrosinase is posited to play a pivotal role in this pathway as it appears to catalyze the first two steps in melanin production: the hydroxylation of tyrosine to DOPA (3,4-dihydroxyphenylalanine) and the oxidation of DOPA to DOPAquinone. These reactions are suggested to be essential for the subsequent production of eumelanin and pheomelanin, the two main types of melanin pigments that determine skin, hair, and eye color and may protect against UV radiation. As mentioned, Decapeptide-12 may act by potentially inhibiting tyrosinase activity. While the precise molecular mechanisms are complex and involve multiple pathways, the basic understanding is that Decapeptide-12 may bind to specific sites on the tyrosinase enzyme or its mRNA, thereby blocking the enzyme's ability to catalyze the aforementioned critical reactions in melanin synthesis. This inhibition could occur through direct interaction with the enzyme, leading to a change in its conformation and reducing its catalytic efficiency. Alternatively, Decapeptide-12 might interfere with the enzyme's gene expression, lowering the amount of functional tyrosinase produced in the melanocytes. Research and Clinical Studies Decapeptide-12 and Melasma One clinical study aimed to evaluate the potential of Decapeptide-12 in test subjects with moderate to severe melasma, solar lentigines, periocular lines, and wrinkles.(1) This 24-week experiment reported apparent improvements in all of the reported facial conditions among the 25 subjects, with sustained impact. Another clinical trial investigated the potential of Decapeptide-12 on mild-to-moderate melasma in 33 test subjects over 16 weeks.(2) Results suggested a visible reduction in the appearance of melasma. Furthermore, one study reported a complete clearance of melasma in 25% of subjects after six weeks of Decapeptide-12 presentation.(3) Decapeptide-12 also was reported by the researchers to exhibit an apparent impact in test subjects with the Fitzpatrick phototype IV skin type and moderate recalcitrant melasma completed.(4) Subjects with Fitzpatrick skin type IV are reportedly some of the most common melasma sufferers. The researchers concluded that: “All […] demonstrated statistically significant improvement in the appearance of melasma and overall facial aesthetics.” Decapeptide-12 and Post-inflammatory Hyperpigmentation A clinical case study on pigmented skin (Fitzpatrick skin type IV) indicated that Decapeptide-12 may possibly accelerate the clearance of post-inflammatory hyperpigmentation compared to placebo.(5) The researchers suggest this might be due to the tyrosinase-inhibiting potential of Decapeptide-12.(6) Decapeptide-12 and Solar Lentigo One study evaluated the impact of Decapeptide-12 in the form of hyperpigmentation called solar lentigines caused by chronic photodamage.(7) The results reported that 38.5% of the models evaluated appeared to have achieved complete clearance, and all subjects appeared to exhibit some improvement. Furthermore, 30.7% of the models were reported to improve from a moderate degree of photodamage to a milder degree, 15.4% improved from a severe degree to a moderate degree, and another 15.4% improved from a severe degree to a milder degree after 24 weeks. Decapeptide-12 and Cell Aging Sirtuins are a family of genes involved in various cellular processes. They are believed to regulate cellular metabolism, DNA repair, inflammation, and stress resistance. One of the most well-known sirtuins is SIRT1, which has been suggested to regulate various biological pathways, such as glucose metabolism, lipid metabolism, and cellular stress responses. Studies have also suggested that SIRT1 may be involved in extending the lifespan in certain model organisms. One of the most promising compounds is resveratrol, found in red wine, and has been suggested to activate SIRT1 in some studies. One study looked at the potential of Decapeptide-12 on sirtuin gene expression levels in keratinocyte progenitors.(8) The researchers used RT-PCR to measure the impact of Decapeptide-12 on seven Sirtuin genes and cellular viability and proliferation after 72-hour incubation with various concentrations of Decapeptide-12. The results suggested that Decapeptide-12 possibly increased the transcription of several Sirtuin genes, including SIRT1, SIRT3, SIRT6, and SIRT7, with reportedly reduced cytotoxicity. The researchers reported that “ decapeptide-12 increased transcription of SIRT1 by 141 ± 11% relative to control cells, whereas levels of SIRT3, SIRT6, and SIRT7 were increased by 121 ± 13%, 147 ± 8% and 95± 14%, respectively.” SIRT1, with a reported increase in transcription by 141 ± 11% may enhance cellular resilience against oxidative stress and inflammation, possibly delaying aging processes on a cellular level. The apparent increases in SIRT3 (121 ± 13%) and SIRT6 (147 ± 8%) transcription levels further amplify the possible research outcomes. SIRT3's potential involvement in mitochondrial function and energy metabolism suggests that decapeptide-12 might enhance mitochondrial efficiency and antioxidant capacity. Similarly, SIRT6 is possibly associated with DNA repair, telomere maintenance, and inflammation regulation. Its potential upregulation might contribute to improved genomic stability and reduced inflammation, potentially further decelerating the aging process in cells. While the reported increase in SIRT7 transcription (95 ± 14%) appears less pronounced, it may still indicate potential influence on nucleolar functions, including ribosome biogenesis and stress sensing. This subtle modulation might also contribute to the overall cellular homeostasis and longevity.(8) Decapeptide-12 is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Jiang, L., Hino, P. D., Bhatia, A., Stephens, T. J., & Jimenez, F. (2018). Efficacy of Trifecting® Night Cream, a Novel Triple acting Skin Brightening Product: A Double-blind, Placebo-controlled Clinical Study. The Journal of clinical and aesthetic dermatology, 11(12), 21–25. Ramírez, S. P., Carvajal, A. C., Salazar, J. C., Arroyave, G., Flórez, A. M., & Echeverry, H. F. (2013). Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. Journal of drugs in dermatology : JDD, 12(6), e106–e110. Hantash, B. M., & Jimenez, F. (2012). Treatment of mild to moderate facial melasma with the Lumixyl brightening system. Journal of drugs in dermatology : JDD, 11(5), 660–662. Hantash, B. M., & Jimenez, F. (2009). A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. Journal of drugs in dermatology : JDD, 8(8), 732–735. Bhatia, A., Hsu, J. T.s, & Hantash, B. M. (2014). Combined delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color. Journal of drugs in dermatology : JDD, 13(1), 84–85. Chen, J., Bian, J., Hantash, B. M., Albakr, L., Hibbs, D. E., Xiang, X., Xie, P., Wu, C., & Kang, L. (2021). Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles. International journal of pharmaceutics, 606, 120868. https://doi.org/10.1016/j.ijpharm.2021.120868 Kassim, A. T., Hussain, M., & Goldberg, D. J. (2012). Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 14(2), 117–121. https://doi.org/10.3109/14764172.2012.672745 Basil, M. H., & Anan, A. U. (2019). Tyrosinase inhibitors with potent anti-senescence activity in human neonatal keratinocyte progenitors. J Dermatol Surg Res Ther, 2019, 30-39. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Triptorelin (2mg)
Triptorelin is a synthetic peptide composed of ten amino acids, similar to gonadotropin-releasing hormones (GnRH).(1) GnRH, secreted by the hypothalamus, is considered by scientists to be responsible for the synthesis and secretion of the follicle-stimulating hormone (FSH) and luteinizing hormone (LH).(2) Triptorelin may act similarly on the pituitary gland to stimulate the synthesis and release of the LH and FSH hormones, both apparently vital for testosterone production in male species and estrogen synthesis in female species.(3) Overview As an agonist analog of GnRH, researchers have suggested that Triptorelin binds to the receptors in the pituitary gland, which may then stimulate the secretion of LH and FSH. This, at first, may cause an upsurge in the initial phase of LH and FSH stimulation. However, it is important to note that Triptorelin is an analog that appears to have upregulated stability and affinity to the receptors than endogenous GnRH. Thus, the receptors eventually may become less sensitive to the compound (i.e., downregulation of the receptors), and Triptorelin may lead to reduced release of LH and FSH. Scientists consider that a reduction in the levels of LH and FSH hormones eventually leads to a decrease in testosterone and estrogen levels. This event may lead to the suppression of steroidogenesis by ovaries and testicles.(4) Researchers suggest that Triptorelin exhibits some potential in sustaining the decline in LH and FSH secretion. Therefore, intermittent exposure to Triptorelin may upregulate hormonal levels, while prolonged exposure may lead to dramatic suppression. Chemical Makeup Molecular Formula: C64H82N18O13 Molecular Weight: 1311.4 g/mol Other Known Titles: 57773-63-4 Research and Clinical Studies Triptorelin Peptide and Hormonal Upregulation It is posited that a single exposure to Triptorelin may, under certain experimental conditions, potentially induce a surge in hormone release from cells by interacting with receptors that control gonadotropin secretion.(5) This single interaction may temporarily reset or stimulate the hypothalamic-pituitary axis, thereby possibly enhancing the secretion of endogenous gonadotropins and subsequent hormonal synthesis. It is hypothesized that Triptorelin might activate signaling pathways that had been previously suppressed or downregulated, possibly leading to an increase in luteinizing hormone release and ultimately fostering the synthesis of androgens. The signaling pathways may be suppressed due to previous exposure to androgenic anabolic agents, which may “have pronounced effects on the male pituitary-gonadal axis, affecting the regulation of production of serum luteinizing hormone (LH) and follicle-stimulating hormone and inducing a state of hypogonadotropic hypogonadism characterized by decreased serum endogenous testosterone production and impaired spermatogenesis”. Studies employing controlled conditions have suggested that even a one-time exposure could serve as a catalyst for restoring or augmenting endogenous hormone production. The underlying biological processes, however, remain complex and may depend on multiple variables that have yet to be fully elucidated. Triptorelin Peptide and Hormonal Suppression Prolonged exposure to triptorelin may, according to various mechanistic hypotheses, alter the normal function of GnRH receptors.(6) Instead of the typical pulsatile pattern that is possibly required to maintain receptor sensitivity, the continuous presence of a GnRH analog might potentially lead to a state of receptor desensitization. This desensitization, as posited by some researchers, may potentially be tied to alterations in receptor trafficking, where receptors may become internalized and apparently not recycled to the cell surface as efficiently. Such a process may diminish their ability to respond to further stimulation, thereby reducing the secretion of upstream hormones, and ultimately lowering the synthesis of downstream hormones. Studies employing controlled research approaches have hinted that this continuous stimulation may induce conformational changes in the receptor or associated signaling proteins. These changes may disrupt the receptor’s normal feedback and resensitization mechanisms. Over time, this condition could result in persistently dampened signaling cascades, potentially leading to less hormonal release and reduced hormone production at later stages in the endocrine pathway. Triptorelin Peptide and Thymus Cells In murine models, GnRH-analog peptides structurally related to Triptorelin have been posited to interact with specific binding sites within thymic compartments, potentially influencing immune-related processes.(7) It is possible that age-related reductions in LHRH-binding sites, coupled with complex endocrine-immune signaling pathways, obscure the precise manner in which Triptorelin might modulate thymic function. The researchers have commented that the peptide may “exert a powerful modulation of immune system function during the physiological decline of immunological capacities.” However, the limited data currently available may stem from the difficulty in separating local thymic actions from broader neuroendocrine influences, as well as from the challenges of elucidating how these peptides apparently alter receptor densities, cellular organization, and the proliferative capacity of T-lymphocyte precursors. Therefore, it remains uncertain how Triptorelin could potentially modulate immunity at the molecular and cellular level. Triptorelin peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: National Center for Biotechnology Information. PubChem Compound Summary for CID 25074470, Triptorelin. Tsutsumi, Rie, and Nicholas J G Webster. “GnRH pulsatility, the pituitary response and reproductive dysfunction.” Endocrine journal vol. 56,6 (2009): 729-37. doi:10.1507/endocrj.k09e-185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307809/ LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Triptorelin. https://www.ncbi.nlm.nih.gov/books/NBK548756/ Lepor, Herbert. “Comparison of single-agent androgen suppression for advanced prostate cancer.” Reviews in urology vol. 7 Suppl 5 (2005): S3-S12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477619/ Pirola I, Cappelli C, Delbarba A, Scalvini T, Agosti B, Assanelli D, Bonetti A, Castellano M. Anabolic steroids purchased on the Internet as a cause of prolonged hypogonadotropic hypogonadism. Fertil Steril. 2010 Nov;94(6):2331.e1-3. doi: 10.1016/j.fertnstert.2010.03.042. Epub 2010 Apr 22. PMID: 20416868. Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center. J Korean Med Sci. 2021 Aug 30;36(34):e219. doi: 10.3346/jkms.2021.36.e219. PMID: 34463062; PMCID: PMC8405405. Marchetti B, Guarcello V, Morale MC, Bartoloni G, Raiti F, Palumbo G Jr, Farinella Z, Cordaro S, Scapagnini U. Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity. Endocrinology. 1989 Aug;125(2):1037-45. doi: 10.1210/endo-125-2-1037. PMID: 2546733. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Thymosin Alpha-1 (5mg / 10mg)
Thymosin Alpha-1 peptide, also known as Thymosin Alpha, TA1, or T α 1, is a fragment of a protein molecule that has been widely studied for its potential implications with the immune system. Researchers have hypothesized that it contributes to the production of T-cells to mitigate and alleviate infection and bacterial spread.(1) Thymosin Alpha-1 is a naturally occurring polypeptide that is considered by researchers to potentially restore and enhance immune functions.(2) Thymosin Alpha-1 is considered to be one of the polypeptides found in Thymosin Fraction 5, which is a crude extract of the thymus gland.(3) Since its discovery, a synthetically developed form of Thymosin Alpha-1 has also been studied, researchers refer to the peptide as Thymalfasin.(2) Thymalfasin is composed of 28 amino acids, similar to the naturally occurring Tα 1, and is derived from a longer polypeptide precursor composed of 113 amino acids, known as Prothymosin Alpha.(3) Overview The main aim of initial research into Thymosin Alpha-1(4) was to understand and examine the immunomodulating potential of the peptide. Studies have suggested that the peptide may increase the concentration of the major histocompatibility complex (MHC) class I and cytokine production, which may possibly lead to increased immune responses. The peptide may also enhance the activity of natural killer cells and foster the expression of phenotypic markers on T cells, suggesting a multi-faceted role in modulating the immune response. The researchers posited that the peptide may also increase the expression of high-affinity receptors for interleukin-2. This could potentially lead to a more vigorous activation and proliferation of T lymphocytes. Researchers speculate that Thymosin Alpha-1 may stimulate possible action by targeting the T-helper cells and cytotoxic T-cell populations.(3) Tα 1 may possibly induce differentiation of the T-cells (thymocytes) and the terminal differentiation of the blood lymphocytes. Scientists posit that it may elevate the production of the natural killer cells and potentially stimulate cytokine mediated inflammation.(2)(3) Furthermore, the peptide has been studied for its potential to enhance efficiency of macrophages and functions as the modulator of the alpha thrombin activity.(3) Specifications Molecular Formula: C129H215N33O55 Molecular Weight: 3108.31 g/mol Other Known Titles: TA1, Tα1, Thymalfasin Research and Clinical Studies Thymosin Alpha-1 Peptide and Immune System In a clinical study,(5) 11 test subjects with different immune system dysfunctions were evaluated for the levels of their natural killer (NK) and lymphokine activated killer cells (LAK) present in their system. It was noted that the immunodeficient subjects demonstrated the mean LAK-cell activity of approximately 65% as compared to the control subjects. Upon presenting Thymosin Alpha-1 to the test subjects, researchers observed that it did not significantly improve the levels of NK or LAK cells. Only 3 test subjects were reported to exhibit improved LAK-cell activity by up to 30% whereas others were not significantly impacted. Thymosin Alpha-1 Peptide and Hepatitis Clinical trials were conducted in test subjects with liver complications, with some exhibiting Hepatitis B & C. Tα 1 was presented to the subjects to explore its potential mechanism of action on these complications.(2) For subjects exhibiting Hepatitis B, it was reported by the research team that when these subjects were presented with Thymosin Alpha-1 twice a week for the duration of the study, the reported virological response rate of the subjects appeared increased by 40.6%. For Hepatitis C, subjects reportedly exhibited improved results when Tα 1 was present in combination with interferon alpha compounds. Thymosin alpha-1's apparent role in modulating the immune system was further explored through its potential engagement with toll-like receptors (TLR)-2 and TLR-9 on dendritic cells and other antigen-presenting cells. This interaction potentially initiates a cascade of immune responses, including the stimulation of cytokines such as interleukin-2 (IL-2), IL-10, and interferon-gamma (IFN-γ), which in turn may support the adaptive immune system. Such modulation is crucial not just for combating infections but also for controlling inflammatory responses, potentially benefiting chronic hepatitis and acute pancreatitis due to its apparent actions on cytokine profiles. In murine models and in vitro studies, Thymosin alpha-1 has been shown to possibly stimulate T-cell maturation and enhance the efficacy of natural killer cells. It might also play a role in reducing inflammatory cytokines such as tumor necrosis factor-alpha, which could be particularly beneficial in chronic inflammatory models. Thymosin Alpha-1 Peptide and Sepsis In a 2015 study,(6) a meta-analysis was conducted where all the relevant clinical trials prior to 2014 were analyzed to understand the possible mechanism of Thymosin Alpha-1 in relation to the sepsis reaction. In this study, 12 controlled trials were evaluated in total. Based on the extracted data and assessment, it was observed by the research analysts that there was a reported significant decline in mortality rate amongst test subjects following introduction to Thymosin Alpha-1. Subsequent studies and systematic reviews, such as those conducted by Yu et al., have supported the hypothesis that Tα1 could alleviate the immunosuppression associated with severe sepsis. However, all these studies were conducted on an exceedingly small pool of test subjects. Given the complex immune dynamics during sepsis, characterized by an initial hyperinflammatory response followed by a phase of immunosuppression, it is plausible that Tα1's potential could be highly dependent on the timing of exposure. Addressing this aspect, further investigations are required to establish a more detailed understanding of how Tα1 influences immune pathways during different stages of sepsis. Thymosin Alpha-1 Research with HIV A study(7) consisted of a randomized phase II open-label clinical trial on 20 clinically stable test subjects. These patients were already undergoing highly active antiretroviral (HAART), alongside which Thymosin Alpha-1 peptide was presented to monitor the impact of the combination. Thymosin Alpha-1 was presented two times in a week in 13 subjects. The remaining 7 subjects were given placebo. Every 2 weeks, the cell counts of CD4/CD8 cells, CD45 cells and signal joint T-cell receptor circles (sjTREC) levels were monitored. After 12 weeks, it was reported by the researchers that there were no apparent significant changes in the levels of CD4, CD and CD45 levels in both the peptide or the placebo group. However, the sjTREC levels reportedly increased in the subjects presented with the peptide. These elevated levels of sjTREC might potentially stimulate immune responses. This increase in sjTREC levels hints at the possibility that Thymosin Alpha-1 may contribute to immune reconstitution by enhancing thymic output. However, this change did not correspond with an increase in total T-cell numbers or significant changes in the proportions of naive and memory T-cell phenotypes. Researchers posited that while the rise in sjTREC levels might indicate a modest improvement in thymopoiesis, the overall recovery and functionality of the T-cell compartment appeared largely unchanged within the duration of this study. Thymosin Alpha-1 and Cancer Cells In a study,(8) the levels of the reactive oxygen species (ROS) were monitored in test models after the presentation of Tα 1. During this study, Thymosin Alpha-1 was presented in mice with liver carcinoma. Both the leukomonocytes and HepG2 cells, given the peptide, were isolated from the mouse spleens, for the purpose of this study. Upon analysis, it was observed by the researchers that the ROS level appeared to be significantly higher in the isolated leuko-monocytes, whereas it was apparently lower in the HepG2 cells. Also, the peptide appeared to possibly increase the levels of the leuko-monocytes, whereas it may have delayed the cell cycle for HepG2 cells and thereby reduced their levels in the system. The study also delved into the possible molecular pathways affected by these changes in the redox state. Particularly, the Akt signaling pathway, known to be influenced by ROS, was examined. It was found that in HepG2 cells, there was a dephosphorylation of Akt at Ser473 following Tα1 exposure, suggesting a decrease in Akt activity associated with lowered oxidative stress. This dephosphorylation of Akt might underpin the reduced proliferation seen in these cancer cells. Another laboratory study focused on lung cancer cells (A549), in order to investigate the potential of Thymosin Alpha-1 on cell proliferation, antioxidant enzyme activities, and cell migration.(9) The study's findings suggest that Thymosin Alpha-1 potentially exhibits an anti-proliferative action on A549 cells, particularly at concentrations of 24 and 48 μg/mL, which apparently led to a reduction in cell viability after 24 hours of exposure. Additionally, Thymosin Alpha-1 is posited to enhance the activity of several key antioxidant enzymes. For instance, increases in the activity levels of catalase were observed at concentrations of 12 μg/mL, suggesting a possible strengthening of the cells' oxidative stress response. The activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) also showed possible enhancements at concentrations of 6 and 12 μg/mL. These findings indicate that Thymosin Alpha-1 might contribute to the cellular antioxidant defense by mitigating the adverse actions of reactive oxygen species (ROS). Regarding cell migration, Thymosin Alpha-1 potentially inhibits the migration of A549 cells in a concentration-dependent manner, as indicated by scratch assays. In terms of ROS production, the study suggests that Thymosin Alpha-1 might lead to a reduction in cellular ROS levels, and this outcome further supports the notion that Thymosin Alpha-1 could play a role in moderating oxidative stress within cancer cells. Thymosin Alpha-1 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Immunodeficiency, British Society for Immunology. Published March 2017. https://www.immunology.org/policy-and-public-affairs/briefings-and-position-statements/immunodeficiency Dominari A, Hathaway Iii D, Pandav K, Matos W, Biswas S, Reddy G, Thevuthasan S, Khan MA, Mathew A, Makkar SS, Zaidi M, Fahem MMM, Beas R, Castaneda V, Paul T, Halpern J, Baralt D. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020 Dec 15;9(5):67-78. doi: 10.5501/wjv.v9.i5.67. PMID: 33362999; PMCID: PMC7747025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747025/ National Center for Biotechnology Information. "PubChem Compound Summary for CID 16130571, Thymalfasin" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Thymalfasin Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007 Sep;1112:14-20. doi: 10.1196/annals.1415.039. Epub 2007 Jun 13. PMID: 17567941. https://pubmed.ncbi.nlm.nih.gov/17567941/ Eckert K, Schmitt M, Garbin F, Wahn U, Maurer HR. Thymosin alpha 1 effects, in vitro, on lymphokine-activated killer cells from patients with primary immunodeficiencies: preliminary results. Int J Immunopharmacol. 1994 Dec;16(12):1019-25. doi: 10.1016/0192-0561(94)90081-7. PMID: 7705963. https://pubmed.ncbi.nlm.nih.gov/7705963/ Li C, Bo L, Liu Q, Jin F. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis. 2015 Apr;33:90-6. doi: 10.1016/j.ijid.2014.12.032. Epub 2014 Dec 19. PMID: 25532482. https://pubmed.ncbi.nlm.nih.gov/25532482/ Chadwick D, Pido-Lopez J, Pires A, Imami N, Gotch F, Villacian JS, Ravindran S, Paton NI. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin Exp Immunol. 2003 Dec;134(3):477-81. doi: 10.1111/j.1365-2249.2003.02331.x. PMID: 14632754; PMCID: PMC1808897. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808897/ Qin Y, Chen FD, Zhou L, Gong XG, Han QF. Proliferative and anti-proliferative effects of thymosin alpha1 on cells are associated with manipulation of cellular ROS levels. Chem Biol Interact. 2009 Aug 14;180(3):383-8. doi: 10.1016/j.cbi.2009.05.006. Epub 2009 May 12. PMID: 19442654. https://pubmed.ncbi.nlm.nih.gov/19442654/ Kharazmi-Khorassani J, Asoodeh A. Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549). Environ Toxicol. 2019 Aug;34(8):941-949. doi: 10.1002/tox.22765. Epub 2019 May 8. PMID: 31067016. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Thyrotropin TRH (25mg)
Thyroid hormones are considered to be growth and metabolism regulators. In order to maintain the synchrony of these regulating mechanisms and hemostasis, hormones released by the hypothalamus are called Thyrotropin-releasing hormone (TRH).(1) This hypothalamic hormone is posited to play a crucial role in the feedback loop that regulates thyroid function. Scientists consider the main function of Thyrotropin-releasing hormone (TRH) to be the stimulation of the pituitary gland to release Thyroid-Stimulating Hormone (TSH) which in turn plays a role in the maintenance of the levels of thyroid hormones.(2) More specifically, TSH acts directly on the thyroid gland to promote the synthesis and release of thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3). While TRH is an endogenous compound, a synthetic peptide was developed with the hopes of simulating TRH characteristics and is known as Thyrotropin, or Protirelin.(3) Overview Thyrotropin is the synthetic analogue of the endogenous peptide hormone Thyrotropin-releasing hormone.(3) Structurally analogous to TRH, Thyrotropin is a tripeptide composed of three amino acid residues connected in a sequential form.(3) Researchers consider Thyrotropin to potentially function via binding to the thyrotropin-releasing hormone (TRH) receptors TRH-1 and TRH-2.(4)(5)(6) This interaction stimulates a cascade of biochemical events within the cell, highlighting the significant impact of these hormonal interactions on overall endocrine system function. On binding with these receptors, which are mediated by G proteins, a possible cascade of signals may be generated. First, a hydrolase enzyme may be activated, which in turn may cause a breakdown of an existing compound, producing inositol. Research indicates that Inositol may bind with another receptor, a calcium channel, thereby resulting in possible increased cellular levels of calcium which may activate protein kinase C, potentially leading to elevated phosphorylation of secondary messenger enzymes. All these signals carry the collective potential to modify gene expression in the nucleus of a cell, which may transduce the TRH binding signal to stimulate the pituitary gland to release TSH, thus regulating thyroid hormone production in the thyroid gland. This detailed mechanism is essential for maintaining metabolic balance and responding to physiological demands. Specifications: Molecular Formula: C16H22N6O4 Molecular Weight: 362.39 g/mol Other Known Titles: Protirelin Research and Clinical Studies Thyrotropin Releasing Peptide and The Central Nervous System Studies have investigated the potential of Thyrotropin-releasing hormone within the central nervous system, particularly its potential to modulate neurotransmitter systems, focusing on its actions in superfused rat hippocampal slices subjected to potassium-induced depolarization.(7) Although specific mechanisms are not fully delineated, Thyrotropin-releasing hormone seems to exert notable actions under certain conditions. The experiments demonstrated that while Thyrotropin-releasing hormone did not modify basal levels of glutamate or aspartate, it significantly inhibited their release during neuronal activation triggered by potassium. This suggests that Thyrotropin-releasing hormone may play a role in controlling the release of excitatory neurotransmitters during heightened neuronal activity, indicative of a modulatory capacity that could be relevant in conditions of neural excitability such as seizures or neurodegenerative states. The observed actions of Thyrotropin-releasing hormone might be mediated through its interaction with high-affinity receptors associated with G-protein coupled receptor pathways, which involve complex intracellular signaling cascades including calcium mobilization. The inhibition of glutamate and aspartate release appears to be calcium-dependent, raising the possibility that Thyrotropin-releasing hormone might influence calcium channels or the associated release machinery. Interestingly, the inhibitory action on neurotransmitter release did not follow a straightforward response curve, suggesting intricate receptor interactions or the influence of additional regulatory mechanisms Thyrotropin Releasing Peptide and Amyotrophic Lateral Sclerosis Researchers are considering the potential function of Thyrotropin in Amyotrophic Lateral Sclerosis (ALS).(8) Researchers suggest that Thyrotropin may act as a neuromodulator during the hyperactivity of the hypothalamic nervous system, which may assert some mitigation of Amyotrophic Lateral Sclerosis (ALS) symptoms.(9) Thyrotropin Releasing Peptide and Behavioral Research Initial clinical studies conducted to assess the potential of the peptide were somewhat hindered as researchers considered the peptide might not be able to cross the blood brain barrier.(10) Scientists consider the blood brain barrier to be one of the most difficult membranes to cross as it is composed of closely spaced cells in order to prevent toxic substances from crossing over and reaching the brain.(11) In this study,(10) the peptide was presented into the spinal theca (or cerebrospinal fluid). Eight test subjects with depressive symptoms were enrolled in a double-blind clinical trial study. Upon analysis, it was observed by the researchers that five out of the eight subjects exhibited an apparent 50% or more reduction in depressive behavior. It is suggested that the peptide's modes of action could potentially be linked to its interactions with certain neurotransmitter systems. Thyrotropin-releasing peptide is hypothesized to affect the pathways of serotonin and dopamine, both of which play significant roles in regulating mood. These actions might be facilitated through TRH receptors, which are prominently found in areas of the brain such as the amygdala and hippocampus, key sites for behavioral regulation. Additionally, it is conceivable that Thyrotropin-releasing peptide could influence these neurotransmitter systems by modifying their synthesis, the release of neurotransmitters, or their reuptake at the points where neurons communicate, known as synapses. Furthermore, Thyrotropin-releasing peptide is reported to exhibit actions on behavior that are contingent upon the existing neural or physiological conditions of the individual. For example, Thyrotropin-releasing peptide may have the capacity to restore balance to both overactive and underactive neural conditions by altering neurotransmitter levels appropriately. This hypothesis is supported by the observations of behavioral enhancements noted in clinical studies like this one, where changes in mood are described as quick yet short-lived, indicating a temporary recalibration of neural processes rather than a permanent alteration. This dynamic response could be indicative of Thyrotropin-releasing peptide’s capacity to adjust to and moderate varying neurological states. In another study,(12) 44 subjects were presented with the "Thyrotropin test". Out of the 44 test subjects, 19 exhibited an apparently blunted response to the test, indicating possible hypothyroidism, whereas 6 exhibited an apparently higher response to the test. Five of these subjects with a high augmented response were reported to naturally produce antithyroid antibodies. Through this study, researchers posited that the peptide may serve to indicate improper functioning of the thyroid gland, or determine any possible behavioral depressors. Thyrotropin Releasing Peptide and Blood Pressure In one clinical study which sought to conduct diagnostic tests on test subjects, it was suggested by the researchers that the peptide might contribute to an elevation in blood pressure rate. In this study,(13) eight subjects were examined one day before, the day after, and four weeks after heart surgery. All these subjects were given Thyrotropin. While the peptide did not appear to induce any significant changes in the levels of heart rate and thyroid hormones, the blood pressure rates reportedly increased on all three days. These results indicate that Thyrotropin may lead to increased blood pressure rates, and hence it is important for the clinical researcher to be aware of the subjects' pre-existing heart conditions when it comes to peptide experimentation. Researchers have further experimented with the peptide to investigate its specific mechanisms.(14) When the preoptic suprachiasmatic nucleus (POS) and the medial preoptic nucleus (pom) in test models were exposed to Thyrotropin, there was a 7% increase in blood pressure and a 19% increase in heart rate observed. The response in these areas was noted to be more pronounced compared to other regions, suggesting a possible localized action of Thyrotropin within these nuclei. Interestingly, different responses were recorded in other areas of the hypothalamus, such as the posterior hypothalamic nucleus (NHP), where Thyrotropin not only increased heart rate but also blood pressure, whereas only heart rate increases were observed in the anterior (NHA) and dorsomedial (NDM) hypothalamic nuclei. Preliminary exploration into the underlying mechanisms suggests that these cardiovascular changes could potentially be mediated by a mix of autonomic nervous system regulations. It is posited that inhibition of the parasympathetic nerves could contribute to the heart rate increases in the POSregion. Conversely, in the NHP area, the response to Thyrotropin is thought to be mediated by adrenal catecholamine release, indicating a role of adrenal hormones in these actions. Further, the study indicates that activation of the cardiac sympathetic nerves may play a role in the NHA region, as responses to Thyrotropin were not prevented by either methylatropine preexposure or adrenalectomy. This observation suggests a potential mechanism whereby Thyrotropin acts through pathways independent of adrenal involvement or parasympathetic inhibition. It is also notable that Thyrotropin’s impact was not uniform across all tested areas, with a decrease in both blood pressure and heart rate observed in a specific pom region (A7050–7400). Thyrotropin peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Shahid MA, Ashraf MA, Sharma S. Physiology, Thyroid Hormone. [Updated 2021 May 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. https://www.ncbi.nlm.nih.gov/books/NBK500006/ Michigan Medicine, University of Michigan Health. March 31, 2020. https://www.uofmhealth.org/health-library/ug1836 National Center for Biotechnology Information. "PubChem Compound Summary for CID 638678, Protirelin" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Protirelin. Boler J, Enzmann F, Folkers K, Bowers CY, Schally AV. The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun. 1969 Nov 6;37(4):705-10. https://pubmed.ncbi.nlm.nih.gov/4982117/ Kobayashi, Naotake et al. “Discovery of the Orally Effective Thyrotropin-Releasing Hormone Mimetic: 1-{N-[(4S,5S)-(5-Methyl-2-oxooxazolidine-4-yl)carbonyl]-3-(thiazol-4-yl)-l-alanyl}-(2R)-2-methylpyrrolidine Trihydrate (Rovatirelin Hydrate).” ACS omega vol. 3,10 (2018): 13647-13666. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217654/ A. Eugene Pekary, Protirelin should be used with care in patients with ischemic heart disease, obstructive airway disease, or severe hypopituitarism (Parfitt, 1999). https://www.sciencedirect.com/topics/medicine-and-dentistry/protirelin Nie Y, Schoepp DD, Klaunig JE, Yard M, Lahiri DK, Kubek MJ. Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. Brain Res. 2005 Aug 23;1054(1):45-54. doi: 10.1016/j.brainres.2005.06.077. PMID: 16055093. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. National Institute of Neurological Disorders and Stroke. Miller SC, Warnick JE. Protirelin (thyrotropin-releasing hormone) in amyotrophic lateral sclerosis. The role of androgens. Arch Neurol. 1989 Mar;46(3):330-5. https://pubmed.ncbi.nlm.nih.gov/2563937/ Marangell LB, George MS, Callahan AM, Ketter TA, Pazzaglia PJ, L'Herrou TA, Leverich GS, Post RM. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry. 1997 Mar;54(3):214-22. https://pubmed.ncbi.nlm.nih.gov/9075462/ Blood-brain barrier. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/blood-brain-barrier Sternbach HA, Gold MS, Pottash AC, Extein I. Thyroid failure and protirelin(thyrotropin-releasing hormone) test abnormalities in depressed outpatients. JAMA. 1983 Mar 25. https://pubmed.ncbi.nlm.nih.gov/6402617/ Zaloga GP, Chernow B, Zajtchuk R, Chin R, Rainey TG, Lake CR. Diagnostic dosages of protirelin (TRH) elevate BP by noncatecholamine mechanisms. Arch Intern. https://pubmed.ncbi.nlm.nih.gov/6428340/ Diz DI, Jacobowitz DM. Cardiovascular effects produced by injections of thyrotropin-releasing hormone in specific preoptic and hypothalamic nuclei in the rat. Peptides. 1984 Jul-Aug;5(4):801-8. doi: 10.1016/0196-9781(84)90025-1. PMID: 6436799. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Syn-AKE (200mg)
Syn-AKE is a synthetic peptide with the sequence beta-alanyl-L-prolyl-3-aminomethyl-L-alanine benzyl amide acetic acid known as tripeptide-3. The structure of Syn-AKE is composed of the amino acids alanine, proline, and diamino butyrate, which are linked by peptide bonds.(1) The peptide is designed to mimic the activity of Waglerin-1, a polypeptide. Waglerin-1 is a muscle relaxant that is considered to block the action of acetylcholine in the neuromuscular junction, leading to a decrease in muscle contractions. When developing Syn-AKE, researchers aimed to develop a peptide with similar activity on muscle contractions as Waglerin-1. The peptide’s intended mechanism of action is temporarily inhibiting muscle contractions, which typically leads to a decrease in the depth of wrinkles on the skin of test subjects. This compound has been extensively researched for its potential anti-aging properties for the skin of various species, including reducing fine lines and wrinkles, improving skin texture, and increasing skin hydration solely because of its muscle-relaxing properties. Chemical Makeup Molecular formula: C23H37N5O7 Molecular weight: 495.57 g/mol Other known titles: Tripeptide-3, Syn-Ake acetate, SYN-AK, DTXSID40231699, EX-A3743 Research and Clinical Studies Syn-AKE Peptide Mechanism of Action Syn-AKE has been reported by researchers to mimic the action of Waglerin-1.(2) Waglerin-1 has been considered to have muscle-relaxant properties. According to researchers, this component is a 22-amino acid polypeptide, and may be potentially selective for the form of nicotinic acetylcholine receptors (nAChRs).(3) The nACh receptors transmit signals from nerve cells to muscle cells, ultimately leading to muscle contractions. By blocking the activity of nAChRs, Waglerin-1 apparently prevents the release of acetylcholine and blocks muscle contraction. Waglerin-1 is also suggested to have modulating impacts on the brain's neurotransmitter gamma-aminobutyric acid (GABA) receptors. These receptors are involved in regulating the activity of neurons and by modulating them, Waglerin-1 may cause significant risks in research settings. Contrastingly, initial research suggests Syn-AKE cannot affect GABA receptors in the brain and may lack the risks of Waglerin-1. Syn-AKE was designed to mimic the activity of Waglerin-1 by targeting the same nAChRs in the neuromuscular junctions. Specifically, Syn-AKE is a tripeptide that contains a sequence of amino acids similar to the region of Waglerin-1 that binds to nAChRs. Syn-AKE is thought to have great permeability through the skin and bind to the nAChRs in the muscles beneath it, possibly preventing them from responding to acetylcholine. Researchers suggest that the peptide may be particularly impactful against expression lines by relaxing facial muscles. According to experimental research, the peptide "was able to reduce the frequency of innervated muscle cell contractions by 82% (...) after 2h of [presentation]."(4) The antagonism of Syn-AKE towards the nAChRs may be reversible.(5)(6) Such a reversal may indicates that the potential of tripeptide-3 on the receptors are temporary and can be reversed once the peptide is no longer present. Syn-AKE Peptide and Fine Lines, Wrinkles According to researchers, Syn-AKE may induce an immediate minimization of muscle contraction, reducing fine lines and wrinkles.(7)(8) A three-month study including 37 female subjects aged 33 to 45 with mild-to-moderate wrinkles reported that Syn-AKE appeared to exhibit both immediate and long-term potential.(9) Assessments indicated statistically significant improvements in wrinkles shortly after presentation and at months 1 and 3. One of the largest studies conducted on Syn-AKE compared its potential with other peptides and a placebo in 45 test subjects. Syn-AKE was reported to exhibit some potential, gradually exhibiting greater action after repeated presentation and reaching more than 50% after four weeks. Researchers suggested that Syn-AKE "showed up to a 52% reduction in the appearance of wrinkle size in test volunteers after a 28-day application of a 4% formulation to the forehead twice a day"(10)(11) Syn-AKE peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Balaev, A. N., Okhmanovich, K. A., & Osipov, V. N. (2014). A shortened, protecting group free, synthesis of the anti-wrinkle venom analogue Syn-Ake exploiting an optimized Hofmann-type rearrangement. Tetrahedron Letters, 55(42), 5745-5747. Molles, B. E., Tsigelny, I., Nguyen, P. D., Gao, S. X., Sine, S. M., & Taylor, P. (2002). Residues in the epsilon subunit of the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the alpha-epsilon subunit interface site. Biochemistry, 41(25), 7895–7906. https://doi.org/10.1021/bi025732d Gorouhi, F., & Maibach, H. I. (2009). Role of peptides in preventing or treating aged skin. International journal of cosmetic science, 31(5), 327–345. https://doi.org/10.1111/j.1468-2494.2009.00490.x Reddy, B., Jow, T., & Hantash, B. M. (2012). Bioactive oligopeptides in dermatology: Part I. Experimental dermatology, 21(8), 563–568. https://doi.org/10.1111/j.1600-0625.2012.01528.x Munawar, A., Ali, S. A., Akrem, A., & Betzel, C. (2018). Snake venom peptides: Tools of biodiscovery. Toxins, 10(11), 474. TATARINGA, G., & ZBANCIOC, A. M. (2021). Antirid peptides in cosmeceutical formula. Romanian Journal of PHARMACEUTICAL PRACTICE| Vol. XIV, 58(3). Chhipa, N. M., & Chaudhari, B. (2012). Toxin as a Medicine. Journal of Current Pharmaceutical Research, 9(1), 11-8. Trookman, N. S., Rizer, R. L., Ford, R., Ho, E., & Gotz, V. (2009). Immediate and Long-term Clinical Benefits of a Treatment for Facial Lines and Wrinkles. The Journal of clinical and aesthetic dermatology, 2(3), 38–43. Reddy, B. Y., Jow, T., & Hantash, B. M. (2012). Bioactive oligopeptides in dermatology: Part II. Experimental dermatology, 21(8), 569–575. https://doi.org/10.1111/j.1600-0625.2012.01527.x Pai, V. V., Bhandari, P., & Shukla, P. (2017). Peptides as cosmeceuticals. Indian Journal of Dermatology, Venereology and Leprology, 83, 9. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
PNC-27 (5mg)
PNC-27 is a 27-amino acid peptide that has been studied for its potential to mitigate the activity and proliferation of cancer cells. It is derived from the third helix of the anti-cancer peptide α-helical segment of p53 (ASPP2), a protein involved in tumor suppression. PNC-27 has been suggested to induce cell death via necrosis in various cancer cell lines, including pancreatic cancer, ovarian cancer, and leukemia, among others. Researchers speculate that the PNC-27 peptide may specifically target cancer cells while not appearing to interact with other cells. Initially synthesized in 2000 as a part of a research project associated with immunodeficiency, specifically HIV, this peptide was reported to exhibit the ability to bind with the double minute (HDM2) protein, which is deemed overly expressed on the membranes of the carcinogenic cells. Interestingly, PNC-27 does not appear to induce apoptosis, a common pathway for many anticancer research chemicals, but rather may act upon the cells via inducing necrosis. This mode of action suggests a direct, physical disruption of the plasma membrane, possibly mediated by the formation of pores that compromise cell integrity, leading to necrosis. More specifically, binding with this protein appears to perforate the membrane of cancer cells by forming holes and causing membranolysis. This allows for the influx of ions and the efflux of cellular contents, ultimately leading to cell death.(1) Chemical Makeup(1) Molecular Formula: C188H293N53O44S Molecular Weight: 4031.7 g/mol Research and Clinical Studies PNC-27 Peptide and Selective Cell Death In 2009, a study aimed to evaluate whether the PNC-27 peptide may interact (and potentially induce necrosis) within non-cancerous cells. The researchers at the time believed that, based on the peptide structure, it might be able to bind with HDM-2 protein and interact singly with cancerous cells. HDM-2 protein is reportedly only present in cancerous cells. The study suggests that forming a 1:1 complex between PNC-27 and HDM-2 might be a key event in initiating the potential formation of transmembrane pores. The study employed theoretical and experimental approaches to understand the pore formation's interaction and structural basis. Conformational energy calculations indicated that PNC-27 might form stable complexes with HDM-2, possibly aligning the leader sequence to not interfere with the core interaction. Yet, it did appear to participate in the pore structure. Immuno-electron microscopy gave researchers visual data of these complexes at the cancer cell surface, with observed ring-shaped structures at the pore sites, which they speculated may contain PNC-27 bound to HDM-2. Importantly, these pore structures were not observed in normal cells exposed to PNC-27, underscoring the peptide's potentially selective toxicity towards cancer cells. Further, for this study, normal cells were implanted with HDM-2 protein. The PNC-27 peptide, which otherwise might not affect the cells, now showed affinity towards the modified cells.(2) PNC-27 Peptide and Lysis of Cancerous Cells Another study(3) conducted in 2010 aimed at understanding whether fragments of the peptide or the entire peptide might impact the formation of membrane pores. The hypothesis was that if the peptide remained intact, it might more effectively induce the membranolytic activity necessary for killing cancer cells. For this study, the peptide was induced with a green fluorescence chemical to the terminal containing an amino group and a red fluorescence chemical to the terminal containing the carboxyl group. This labeling strategy was crucial as it allowed the researchers to visually track the integrity of the peptide within the cellular environment. The breast tumor and control cells were then exposed to the modified peptide to see which color appeared on the membrane during membranolysis. Half an hour after the peptide, a bright yellow luminescence was reported upon membrane lysis, suggesting that the peptide was fully intact during this cellular membrane-killing process. This observation was critical as it suggested that the peptide's structure was preserved during the interaction with the cell membrane, which would be essential for any cytotoxic activity. As expected, this was only seen in the cancerous cells while the control cells remained viable. The study's researchers suggest that the intact form of PNC-27 may be crucial for its activity, as the peptide appears to selectively induce pore formation in cancer cell membranes—a process associated with the release of lactate dehydrogenase (LDH), a marker of cell lysis. The interaction of PNC-27 with cancer cell membranes was suggested to increase over time, correlating with increased LDH release and cell death. Kelley A. Sookraj et al. stated, "PNC-27 induces cancer cell membrane lysis by acting as the unmodified peptide, not fragments. The punctate yellow fluorescence is due to the interaction of PNC-27 with intramembrane targets of MCF-7 cells that do not exist in the membrane of the untransformed cell line. This interaction increases the lifetime of PNC-27. The absence of these targets in the membranes of the untransformed MCF-10-2A cells results in the initial uniform fluorescence of the double-labeled peptide in their membranes, after which the peptide is degraded." (3) PNC-27 Peptide and Non-solid Tumor Cells In 2014, another study(4) was initiated to determine the potential of the PNC-27 peptide on non-solid tissue tumor cells. As mentioned in the study, the purpose was “twofold: to investigate if these cells likewise express HDM-2 in their plasma membranes and to determine if our anti-cancer peptide induces tumor cell necrosis in these non-solid tissue tumor cells in a manner that depends on the interaction between the peptide and membrane-bound HDM-2.”(4) The non-solid tumor cells were exposed to PNC-27, and the action examined. As part of the control, murine leukocyte cells were used. Upon macroscopic analysis, it was suggested that the HDM-2 cells were expressed in the non-solid tissue tumor cells and that the PNC-27 peptide appeared to exhibit potential selectivity towards these cells. Researcher Katlin Davitt et al. stated: "... We conclude that the association of PNC-27 with HDM-2 in the cancer cell membrane [may] result in trans-membrane pore formation, which results in cancer cell death, as previously discovered in a number of different solid tissue tumor cells. Since K562 cells lack p53 expression, these effects of PNC-27 on this leukemia cell line [may] occur by a p53-independent pathway." (4) PNC-27 Peptide and Cancer Cells A study(5) was conducted on the peptide PNC-28, which is structurally and functionally very similar to the PNC-27 peptide. Both peptides are derived from p53 and appear to act only on the HDM-2 proteins in cancerous cells. In this study, the researchers evaluated the anti-tumor activity of PNC-28 against ovarian cancer cells and mouse xenograft models. They suggested that PNC-28 appeared to inhibit the growth of ovarian cancer cells and reduced tumor size in the mouse models. In another 2020 study,(6) an experiment was conducted to determine the PNC-27 peptide potential on non-stem cells from the leukemia cell lines. Researchers reported the study focused on “acute myelogenous leukemia cell lines: U937, acute monocytic leukemia; OCI-AML3, acute myelomonocytic leukemia and HL60, acute promyelocytic leukemia.” These particular cell lines were selected due to their distinct phenotypic and genotypic characteristics, which might shed light on the peptide's varying potential across different cancer cell types. After peptide exposure, it was observed that the HDM-2 protein appeared to be highly expressed in all leukemia cells, which were all targeted by the PNC-27 peptide.(6) PNC-27 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References Davitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grin'kina N, Orynbayeva Z, Shaikh MF, Adler V, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Ann Clin Lab Sci. 2014 Summer;44(3):241-8. PMID: 25117093. https://pubmed.ncbi.nlm.nih.gov/25117093/ Sarafraz-Yazdi E, Mumin S, Cheung D, Fridman D, Lin B, Wong L, Rosal R, Rudolph R, Frenkel M, Thadi A, Morano WF, Bowne WB, Pincus MR, Michl J. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines. 2022; 10(5):945. https://doi.org/10.3390/biomedicines10050945 Sookraj KA, Bowne WB, Adler V, Sarafraz-Yazdi E, Michl J, Pincus MR. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemother Pharmacol. 2010 Jul;66(2):325-31. doi: 10.1007/s00280-009-1166-7. Epub 2010 Feb 25. PMID: 20182728. https://pubmed.ncbi.nlm.nih.gov/20182728/ Davitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grin'kina N, Orynbayeva Z, Shaikh MF, Adler V, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Ann Clin Lab Sci. 2014 Summer;44(3):241-8. PMID: 25117093. https://pubmed.ncbi.nlm.nih.gov/25117093/ Wilbur B. Bowne et al., The Penetratin Sequence in the Anti-cancer PNC-28 Peptide Causes Tumor Cell Necrosis Rather Than Apoptosis of Human Pancreatic Cancer Cells, Annals of Surgical Oncology 15(12):3588–3600 Published by Springer Science+Business Media, LLC 2008 The Society of Surgical Oncology, Inc. DOI: 10.1245/s10434-008-0147-0. https://webs.iiitd.edu.in/raghava/cancerppd/refpdf/18931881.pdf Anusha Thadi et al, Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells, Anticancer Research 40 (9):4857-4867, September 2020 DOI: 10.21873/anticanres.14488 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg)
Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin are all synthetic peptides which, albeit via different proposed mechanisms, have exhibited potential to stimulate growth hormone (GH) synthesis and secretion. Tesamorelin, a synthetic analogue of the growth hormone-releasing hormone (GHRH), appears to act by specifically stimulating the production and release of endogenous growth hormone (GH) due to its potential binding affinity for GHRH receptors. Structurally, Tesamorelin is a chain of 44 amino acids, containing a sequence that bears resemblance to GHRH. Intriguingly, modifications have been introduced to Tesamorelin to possibly fortify its defense against enzymatic breakdown. For instance, its C-terminus showcases a trans-3-hexenoic acid group alteration, a change sometimes referred to as an omega-amino acid modification, which is suggested to bolster the peptide's resilience to enzymatic degradation. Further, Tesamorelin's N-terminus is adorned with an acetyl group (CH₃CO-), a modification that might further amplify the molecule's stability and biological efficacy. Consequently, this peptide garners the designation N-(trans-3-hexenoyl)-[Tyr1]hGRF(1–44)NH2 acetate. When engaging with GHRH receptors located in regions like the pituitary and hypothalamus, it is theorized that Tesamorelin may stimulate the secretion of HGH from the resident pituitary cells. CJC-1295 (Mod GRF 1-29) is a synthetic peptide that appears to exhibit prolonged half-life as it is likely to resist enzymatic degradation. It is also known as CJC-1295 without DAC (Drug Affinity Complex). References suggest it as a tetrasubstituted variant of the shortest functional GHRH sequence, denoted GRF (1-29). Consequently, it is posited that this molecule may potentially engage with GHRH receptors on pituitary cells, possibly influencing the release of hGH. Research indicates that the peptide appears to act as a potent stimulator of GH secretion, similar to GHRH, which may show promise in promoting protein synthesis, muscle growth, and enhanced metabolic processes. Ipamorelin, a synthetic pentapeptide, appears to act as a selective agonist for the ghrelin receptor and may stimulate the release of GH. This is because ghrelin receptors are found in the pituitary gland, where they are called growth hormone secretagogue (GHS) receptors. It appears to display high specificity and minimal action on other hormonal systems, making it a target for research in GH stimulation. Chemical Makeup (1)(2)(3) Molecular Formula: Tesamorelin: C221H366N72O67S CJC-1295 (Mod GRF 1-29): C152H252N44O42 Ipamorelin: C38H49N9O5 Molecular Weight: Tesamorelin: 5136 g/mol CJC-1295 (Mod GRF 1-29): 3367.9 g/mol Ipamorelin: 711.8 g/mol Sequence Tesamorelin: Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 CJC-1295 (Mod GRF 1-29): L-tyrosyl-D-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide Ipamorelin: alpha-methyl-alanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide Other Known Titles CJC-1295 (Mod GRF 1-29): CJC 1295 with DAC Ipamorelin: Ipamorelin Acetate Research and Clinical Studies Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend and the Pituitary Gland The Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin peptide blend appear to exhibit significant interactions with the pituitary gland, seemingly exerting potential impact through specific receptor binding and subsequent modulation of growth hormone (GH) release. Tesamorelin & CJC-1295 (Mod GRF 1-29) appear to engage with GHRH receptors through intricate molecular processes, potentially initiating various signaling pathways. Upon interaction with the GHRH receptor, it is posited that Tesamorelin & CJC-1295 (Mod GRF 1-29) may cause shifts in receptor configuration, possibly instigating intracellular communication channels.(4) There is suggestion amongst researchers that Tesamorelin & CJC-1295 (Mod GRF 1-29) might promote the generation of cyclic adenosine monophosphate (cAMP) within specific target cells. This may potentially be facilitated by the activation of adenylate cyclase, which might transform ATP to cAMP. Elevated cAMP levels are believed to possibly activate protein kinase A (PKA), a molecule that appears integral to intracellular signaling. PKA might then phosphorylate a range of target proteins, setting off subsequent cellular reactions. The hypothetical activation of the GHRH receptor by Tesamorelin & CJC-1295 (Mod GRF 1-29), coupled with the proposed cAMP-PKA signaling sequence, may stimulate hGH production and dispersal from somatotrophs located in the pituitary gland. The HGH secreted from these cells may also play a role in the formation of insulin-like growth factor-1 (IGF-1).(5) CJC-1295 (Mod GRF 1-29) peptide has four amino acid substitutions in its structure, which appears to enhance its GH-related activity as well as its potential resistance towards the proteolytic enzymes. These modifications are also believed to assist “at least 90% of the peptide” to bind covalently to blood albumin, with trace amounts potentially binding to fibrinogen and immunoglobulin G (IgG).(5) As per the researchers, “No other chemical species have been found bound to DAC-GRF after administration This binding extends the half-life of the active pharmacophore, resulting in a markedly prolonged duration of action in several animal species.”(5) Ipamorelin, on the other hand, appears to act as a selective agonist for the GHS (ghrelin) receptor, which is also present on somatotrophs within the pituitary gland. Its binding to GHS (ghrelin) receptors is believed to induce GH release with high specificity and minimal impact on other hormonal systems. Research-based outcomes have indicated that Ipamorelin influence in certain test models may lead to increased GH secretion, without significantly affecting prolactin, or ACTH levels.(6) In vitro analyses indicate that Ipamorelin's interaction with GHS receptors possibly influences somatotroph cells within the anterior pituitary gland. This interaction appears to initiate a series of intracellular signaling cascades. One posited mechanism is the activation of phospholipase C (PLC), which, according to some researchers, might subsequently facilitate the release of inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 might then prompt the release of calcium ions (Ca2+) from intracellular reserves, whereas DAG potentially activates protein kinase C (PKC). Such elevation in intracellular calcium and the probable activation of PKC are suggested to culminate in the observed exocytosis of vesicles containing growth hormone from pituitary cells.(7) Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend and the GI Tract Ipamorelin is believed to primarily interact with the ghrelin receptor within the GI tract. Upon binding to the ghrelin receptors, Ipamorelin may elicit a variety of responses including promoting gut motility and improving intestinal absorption. Moreover, Ipamorelin has shown promise in attenuating inflammation and promoting tissue repair in various models of GI injury. As per researchers, Ipamorelin may “increase total body fat percentages” , identifying the peptide as a “potent and selective stimulator of GH that can significantly influence the GI system, body composition, and adiposity.”(6) Investigators explored the potential impacts of Ipamorelin on gastric functions, contrasting its effects with a placebo. They were particularly interested in its suggested ability to hasten gastric emptying. To assess this, they utilized a method that monitored leftover radioactivity in the stomach a quarter-hour after introducing a particular substance via intragastric gavage. It appears that abdominal surgeries might potentially slow down gastric emptying, an effect that was notably evident in the placebo group. In comparison, Ipamorelin seemed to accelerate this process. Such findings hint at Ipamorelin's potential to boost the pace of gastric emptying. Further, the group aimed to understand how this compound influenced the contractile behavior of gastric smooth muscles when exposed to acetylcholine and electrical field stimulation. Information gathered indicated that intestinal surgeries might notably reduce the contractile reactions to these simulations. However, this suppression appeared to be lessened when Ipamorelin was combined with ghrelin. This raises the possibility that Ipamorelin may not only promote gastric muscle contractility but also possibly offset the inhibitory effects resulting from certain surgical procedures. (8) Synergistic Action of Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend The rationale for combining these peptides lies in their supposed distinct mechanisms of action and potential to enhance growth hormone (GH) secretion synergistically. The apparent synergy of all these peptides lies in their individual potential to increase lean mass and muscle growth. For example, a recent scientific investigation proposed that the potential impacts of Tesamorelin on muscle tissue integrity may be examined using CT scans. Following a placebo-controlled experiment, the CT-scan findings suggest a possible association between Tesamorelin and improvements in muscle density and size. Notably, some muscle groups, especially the rectus abdominis, psoas major, and paraspinal muscles, reportedly showed more evident changes. These changes were characterized by either an increase in muscle size and density or a reduction in fat content. Statistically, these alterations were different compared to the placebo group. Although some theorize that Tesamorelin's effects might be related to molecules like IGF-1, the study did not find a notable connection between changes in IGF-1 levels and shifts in muscle size or density.(9) Further, preliminary research involving CJC-1295 (Mod GRF 1-29) 1-29 indicates a potential rise in nocturnal growth hormone levels, as well as serum levels of IGF-I and IGFBP-3, and GHBP concentrations.(10) Consequently, male research models exposed to the peptide over a span of four months seemingly gained an average of 1.26 kg in lean body mass. Additionally, research suggests that the peptide might influence an increase in skin thickness among males and may possibly enhance insulin sensitivity. Similarly, preliminary studies have suggested that Ipamorelin might exhibit effects similar to those seen with Tesamorelin concerning skeletal muscle and bone structures. However, these findings are still awaiting further confirmation. Going further, there is a working hypothesis amongst researchers that Ipamorelin may interact with, and possibly increase, IGF-I levels. These interactions appeared to align with an increase in muscle fiber size, overall muscle mass, and hence, a potential boost in skeletal muscle strength during this mouse-based study.(11) Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 56841945. https://pubchem.ncbi.nlm.nih.gov/compound/56841945. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 16137828, Tesamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin. Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. The Annals of pharmacotherapy, 46(2), 240–247. https://doi.org/10.1345/aph.1Q629 Zhou, F., Zhang, H., Cong, Z., Zhao, L. H., Zhou, Q., Mao, C., Cheng, X., Shen, D. D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., ... Wang, M. W. (2020). Structural basis for activation of the growth hormone-releasing hormone receptor. Nature communications, 11(1), 5205. https://doi.org/10.1038/s41467-020-18945-0 Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108996/ Jiménez-Reina, L., Cañete, R., de la Torre, M. J., & Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 17(3), 707–714. https://doi.org/10.14670/HH-17.707 Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E., & Pietra, C. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 4, 149–155. https://doi.org/10.2147/JEP.S35396 Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766405/ Khorram, O., Laughlin, G. A., & Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943 Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 11(5), 266–272. https://doi.org/10.1054/ghir.2001.0239 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
GHK-Cu (Copper) (50mg)
GHK-Cu is a naturally occurring copper-binding peptide composed of 3 amino acids, i.e. glycyl-L-histidyl-L-lysine.(1) -Cu refers to the chemical addition of copper. GHK-Cu (Copper) is a small tripeptide found in plasma and reportedly releases at the time of injury. The concentration of GHK-Cu declines with age. At 20 years, the average concentration of GHK-Cu of 200 ng/mL declines to 80 ng/mL by 60 years.(1) Studies(4) have suggested when the plasma GHK peptide is added to the cell culture in nanomolar amounts; the peptide has the potential to induce a wide range of responses from growth stimulation to toxic cell differentiation. During the isolation of the peptide, researchers suggested that it exhibited potential chelating properties and might co-isolate with almost the same amount of copper ions and a fifth of the amount of iron found in the cells. When the peptide was incubated in the isolated cells as a bound complex with copper and iron molecules, maximal potential was reported. Overview Studies(5) have suggested that the peptide exhibits potential in gene expression and may to reset elements of the genome. By this potential mechanism, GHK-Cu peptide may restore impaired cells, including carcinogenic cells and COPD cells. GHK-Cu peptide has been researched for its potential across a variety of functions(1) including that it may tighten and reverse the thinning of aging skin structure, supporting the extracellular matrix, that it may restore the skin barrier and moderate texture, hyperpigmentation and lesions, may support tissue repair and mitigate inflammation, may stimulate increasing hair follicle size, may exert antioxidant properties and, finally, may exhibit gene restructuring potential. Specifications Molecular Formula: C14H23CuN6O4 Molecular Weight: 340.38 g/mol Other Known Titles: glycyl-L-histidyl-L-lysine-copper 2+ Research and Clinical Studies GHK Peptide Initial Research This 1980s study(6) suggested the biological potential of the naturally occurring peptide in tissue repair. GHK peptide may host copper (II) ions due to possible copper affinity and may thereby stimulate the synthesis of collagen and increase the accumulation of total proteins and DNA at the injury site. Dermal wounded rats were used for this study. At the time of injury, the release of GHK peptide was induced. ‘Emergency response molecules’ were released from the matrix at the site of injury. Once released, GHK appeared to bind with Cu ions found in the blood and then stimulate the synthesis of decorin protein. Decorin protein is responsible for the synthesis of collagen and regulation of wound healing and anti-tumor defense mechanism. Further studies in the 2000s,(7) suggested that the GHK-Cu peptide hosts the potential to not only stimulate the collagen synthesis but also stimulate the production of tissue inhibitors, TIMP-1 and TIMP-2. GHK Peptide and Tissue Repair In this study,(8) the main aim was to understand the action of the GHK-Cu peptide complex when applied to the open wounds in comparison to zinc oxide. 18 New Zealand white rabbits were used for this study, divided into three groups – one group was presented with GHK-Cu, second group with zinc oxide and third group with placebo. Woulds were induced on each rabbit and the rabbits were presented with the respective compounds for 21 consecutive days. After 21 days, it was suggested by the researchers that the group delivered with the GHK-Cu peptide complex appeared to exhibit increased healing compared to the group given zinc oxide or placebo. In this study,(9) the main aim was to understand the action of the GHK-Cu peptide complex as compared to helium neon laser. Laser applications were measured at 1 J cm2 and 3 J cm2. 24 New Zealand white rabbits were used for this study, divided into three groups and presented with respective concentrations of the GHK-Cu peptide complex and helium neon laser application. Experimental wounds were created on all the rabbits and all rabbits were studied for 28 consecutive days with the respective compounds. After the study, it was suggested by the researchers that rabbits studied with GHK-Cu peptide and higher concentration of the laser application appeared more receptive toward wound healing than the other group. The rabbits presented with GHK-Cu peptide exhibited an apparent decline in neutrophil counts and increase in neovascularization. GHK Peptide and Metastasis In this 1983 study,(1) the actions of the mixture of GHK-Cu complex and ascorbic acid (Vitamin C) on the growth of the sarcoma (tumor) cells was observed. 180 mice with cancerous growths were exposed to this mixture. Researchers suggested the mixture had the potential to induce a decline in the growth of carcinogenic cells in the subject mice. It was later reported by the researchers that GHK-Cu peptide complex exhibited some potential in increasing the expression of caspase and the associated genes, as well as gene expression associated with DNA repair. Specifically, this peptide seemed to suppress the growth of two types of cancer cells in experimental settings: SH-SY5Y neuroblastoma cells, which are a model for studying nerve cell behavior and pathology, and U937 histiocytic lymphoma cells, which are used to study the immune system's response to cancer. Additionally, the peptide might have reactivated the apoptosis pathway, a type of programmed cell death crucial for removing faulty cells, as evidenced by activity in caspases 3 and 7, which are enzymes that play key roles in apoptosis. Conversely, in a study of non-cancerous cells, GHK appeared to promote the growth of NIH-3T3 fibroblasts, which are healthy cells often used as a standard model to examine cell division and growth. GHK Peptide and Ulcers This clinical study(10) was carried out in diabetic subjects with neuropathic ulcers. All subjects were enrolled in a standard wound care protocol, where only the subjects with sharp ulcer wound or debridement were entered into this randomized, placebo controlled clinical trial. The study was carried out using GHK-Cu peptide complex gel. All subjects were divided into different groups, where one group was presented with the peptide gel, whereas others were given standard care with a placebo application. Following the study, researchers suggested that the subjects given the gel exhibited apparently elevated healing at 98%+. The gel complex appeared to have the potential to induce closure of 98.5% of plantar ulcers whereas the control only reportedly induced 60.8% of ulcer healing. GHK Peptide and Behavioral Properties In this study,(1) GHK-Cu was delivered to mice to measure pain mitigation. Mice were placed on a moderately hot plate. Due to heat and the pain, it would usually take longer for mice to lick their paws; however, upon delivery the peptide, the time taken to lick their paws reduced compared to control environments. Researchers suggested the mice got ‘comfortable’ and their pain was eased faster with the presence of GHK-Cu. In this study,(11) male rats were deposited into a maze, which was intended to induce anxiety and cause behavioral changes. If anxious, rats were observed to restrict arm movement, keeping "close arms"; whereas "open arm" behavior was shown in rats with lessened levels of anxiety. As a part of the study, once the peptide was delivered, the time spent by the rats in "open arms" state in the maze was monitored. After the study, it was reported by the researchers that the peptide exhibited some potential in increasing "open arms" states in the subjects. In an additional study,(12) two rats were placed in a small cage and were then given minor electric shocks. As a result of these shocks, the rat would become agitated and attack the second rat. Twelve minutes before this experiment, GHK-Cu peptide was delivered to both rats. It was noted by the researchers that the number of attacks, after the electric shocks, reduced by 5 times than usual. GHK-Cu and Antioxidative potential A study has investigated the potential of Glycyl-L-histidyl-L-lysine (GHK) to regulate the presence of reactive oxygen species (ROS) within laboratory cells, with a focus on its ability to mitigate oxidative stress through interactions with various ROS types.(13) GHK is proposed to act as an endogenous antioxidant, potentially due to its selective targeting and neutralization of certain radicals, specifically hydroxyl (·OH) and peroxyl (ROO·) radicals. The antioxidant properties of GHK were assessed using two primary techniques: flow cytometry, a method for analyzing various cellular characteristics, and electron spin resonance (ESR) spin-trapping, which is employed to detect free radicals. Throughout these evaluations, GHK appeared to lower ROS levels induced by tert-butyl hydroperoxide (t-BOPD), a chemical known to promote oxidative stress within cells. The ESR data revealed that GHK was notably positive in reducing the concentrations of ·OH and ROO· radicals, although it had a seemingly modest action on superoxide (O2 -·) radicals. Additional examinations utilizing ESR assessed the relative potential of GHK in neutralizing ·OH radicals compared to other antioxidants like carnosine and reduced glutathione (GSH), both recognized for their antioxidant capabilities. Preliminary results suggest that GHK could be more proficient at neutralizing ·OH radicals compared to these alternatives. GHK-Cu and Antioxidative potential A study has investigated the possible mechanisms through which the peptide complex GHK-Cu could influence anti-inflammatory actions, particularly against lung tissue inflammation induced by cigarette smoke (CS).(14) It is hypothesized that GHK-Cu may influence various biochemical pathways and molecular markers related to inflammation and oxidative stress, although the specific mechanisms remain somewhat uncertain. In experiments involving mouse models exposed to CS, exposure to GHK-Cu was linked to a potential decrease in the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), found in bronchoalveolar lavage fluid—fluid used to capture cells and soluble factors from the airways and lung tissues. These results tentatively suggest that GHK-Cu might help mitigate the inflammatory responses triggered by cigarette smoke. Additionally, there was a noted possible reduction in the activity of myeloperoxidase (MPO), an enzyme that serves as a marker for neutrophil-driven inflammation and oxidative stress, in lung tissues that received GHK-Cu exposure. This observation could indicate a potential role of GHK-Cu in limiting the activation or mobilization of neutrophils, possibly curtailing the oxidative bursts and consequent inflammation. At the molecular level, the research proposes that GHK-Cu may interact with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. NF-κB plays a critical role in the initiation and perpetuation of inflammation. The peptide complex is thought to possibly inhibit NF-κB activation by affecting the phosphorylation of IκBα, a protein that inhibits NF-κB. This interaction could hypothetically result in lower expression of genes that promote inflammation, controlled by NF-κB. Furthermore, the study suggests that GHK-Cu could potentially influence the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Nrf2 is integral to cellular defenses against oxidative damage. GHK-Cu is posited to possibly boost the expression and nuclear translocation of Nrf2 in lung tissues, thereby promoting the transcription of genes that combat oxidative stress and possibly enhancing the cellular resilience against oxidative damage. The investigation further examines how GHK-Cu interacts with markers of oxidative stress, such as malondialdehyde (MDA) and glutathione (GSH). MDA is a product of lipid peroxidation and an indicator of oxidative stress, while GSH is a vital antioxidant that plays a crucial role in cellular defense mechanisms. The experimentation with GHK-Cu is associated with a tentative reduction in MDA levels and a possible restoration of GSH levels, suggesting a potential ameliorative action on oxidative stress. GHK-Cu and Lipid Peroxidation A theoretical model posits that GHK could play a role in mitigating the discharge of iron from ferritin.(15) Ferritin, a protein complex that stores iron, releases it in a form that can facilitate lipid peroxidation, a process where free radicals attack lipids, leading to cell damage. It is suggested that GHK might inhibit the assembly of iron complexes within injured tissues, which could, in turn, decrease inflammation. Further exploration of GHK's role reveals that it may interact with specific biological pathways that govern the release of iron from ferritin. This interaction might restrict the release of iron by up to 87%, although this is a provisional estimate. Such a significant reduction in iron release could conceivably diminish both inflammation and oxidative stress, the latter being a condition where damaging oxidative processes occur more rapidly than the body's ability to counteract them, in the affected tissues. GHK-Cu peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Pickart, Loren, and Anna Margolina. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International journal of molecular sciences vol. 19,7 1987. 7 Jul. 2018, doi:10.3390/ijms19071987. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073405/ Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980 Dec 25;288(5792):715-7. doi: 10.1038/288715a0. PMID: 7453802. https://pubmed.ncbi.nlm.nih.gov/7453802/ L.O. Pilgeram, L.R. Pickart, Control of fibrinogen biosynthesis: The role of free fatty acid, Journal of Atherosclerosis Research, Volume 8, Issue 1, 1968, Pages 155-166, ISSN 0368-1319, https://doi.org/10.1016/S0368-1319(68)80089-4 Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980 Dec 25;288(5792):715-7. doi: 10.1038/288715a0. PMID: 7453802. https://pubmed.ncbi.nlm.nih.gov/7453802/ Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. doi: 10.1155/2014/151479. Epub 2014 Sep 11. PMID: 25302294; PMCID: PMC4180391. https://pubmed.ncbi.nlm.nih.gov/25302294/ Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988 Oct 10;238(2):343-6. doi: 10.1016/0014-5793(88)80509-x. PMID: 3169264. https://pubmed.ncbi.nlm.nih.gov/3169264/ Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000 Sep 22;67(18):2257-65. doi: 10.1016/s0024-3205(00)00803-1. PMID: 11045606. https://pubmed.ncbi.nlm.nih.gov/11045606/ Cangul IT, Gul NY, Topal A, Yilmaz R. Evaluation of the effects of tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Vet Dermatol. 2006 Dec;17(6):417-23. doi: 10.1111/j.1365-3164.2006.00551.x. PMID: 17083573. https://pubmed.ncbi.nlm.nih.gov/17083573/ Gul NY, Topal A, Cangul IT, Yanik K. The effects of tripeptide copper complex and helium-neon laser on wound healing in rabbits. Vet Dermatol. 2008 Feb;19(1):7-14. doi: 10.1111/j.1365-3164.2007.00647.x. PMID: 18177285. https://pubmed.ncbi.nlm.nih.gov/18177285/ Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994 Oct;2(4):259-69. doi: 10.1046/j.1524-475X.1994.20406.x. PMID: 17147644. https://pubmed.ncbi.nlm.nih.gov/17147644/ Bobyntsev II, Chernysheva OI, Dolgintsev ME, Smakhtin MY, Belykh AE. Anxiolytic effects of Gly-His-Lys peptide and its analogs. Bull Exp Biol Med. 2015 Apr;158(6):726-8. doi: 10.1007/s10517-015-2847-3. Epub 2015 Apr 23. PMID: 25900608. https://pubmed.ncbi.nlm.nih.gov/25900608/ Sever'yanova LА, Dolgintsev ME. Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats. Bull Exp Biol Med. 2017 Dec;164(2):140-143. doi: 10.1007/s10517-017-3943-3. Epub 2017 Nov 27. PMID: 29181666. https://pubmed.ncbi.nlm.nih.gov/29181666/ Sakuma, S., Ishimura, M., Yuba, Y., Itoh, Y., & Fujimoto, Y. (2018). The peptide glycyl-ʟ-histidyl-ʟ-lysine is an endogenous antioxidant in living organisms, possibly by diminishing hydroxyl and peroxyl radicals. International journal of physiology, pathophysiology and pharmacology, 10(3), 132–138. Zhang, Q., Yan, L., Lu, J., & Zhou, X. (2022). Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in molecular biosciences, 9, 925700. https://doi.org/10.3389/fmolb.2022.925700 Miller, D. M., DeSilva, D., Pickart, L., & Aust, S. D. (1990). Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Advances in experimental medicine and biology, 264, 79–84. https://doi.org/10.1007/978-1-4684-5730-8_11 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.